Drug Therapy, Combination
"Drug Therapy, Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapy with two or more separate preparations given for a combined effect.
| Descriptor ID |
D004359
|
| MeSH Number(s) |
E02.319.310
|
| Concept/Terms |
Drug Therapy, Combination- Drug Therapy, Combination
- Combination Chemotherapy
- Drug Polytherapy
- Drug Polytherapies
- Polytherapies, Drug
- Polytherapy, Drug
- Therapy, Combination Drug
- Chemotherapy, Combination
- Chemotherapies, Combination
- Combination Chemotherapies
- Combination Drug Therapy
- Combination Drug Therapies
- Drug Therapies, Combination
- Therapies, Combination Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Therapy, Combination".
Below are MeSH descriptors whose meaning is more specific than "Drug Therapy, Combination".
This graph shows the total number of publications written about "Drug Therapy, Combination" by people in this website by year, and whether "Drug Therapy, Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 3 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 4 | 4 |
| 2004 | 2 | 4 | 6 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 11 | 11 |
| 2011 | 0 | 9 | 9 |
| 2012 | 0 | 8 | 8 |
| 2013 | 0 | 10 | 10 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 15 | 15 |
| 2016 | 1 | 11 | 12 |
| 2017 | 0 | 10 | 10 |
| 2018 | 0 | 12 | 12 |
| 2019 | 0 | 14 | 14 |
| 2020 | 0 | 6 | 6 |
| 2021 | 2 | 10 | 12 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Therapy, Combination" by people in Profiles.
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
-
Assessment of three antibiotic combination regimens against Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries. Nat Commun. 2024 May 10; 15(1):3947.
-
Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426.
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
-
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024 May 02; 68(5):e0158323.
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
-
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials. 2023 Jun 06; 24(1):382.
-
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 06; 129:107173.
-
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790.
-
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.